- Home
- QNCX vs RVPH Comparison
QNCX vs RVPH Comparison
Compare QNCX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- RVPH
- Stock Information
- Founded
- QNCX 2012
- RVPH 2006
- Country
- QNCX United States
- RVPH United States
- Employees
- QNCX N/A
- RVPH N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- RVPH Health Care
- Exchange
- QNCX Nasdaq
- RVPH Nasdaq
- Market Cap
- QNCX 47.7M
- RVPH 32.8M
- IPO Year
- QNCX 2019
- RVPH N/A
- Fundamental
- Price
- QNCX $1.61
- RVPH $0.36
- Analyst Decision
- QNCX Strong Buy
- RVPH Strong Buy
- Analyst Count
- QNCX 5
- RVPH 5
- Target Price
- QNCX $8.00
- RVPH $9.00
- AVG Volume (30 Days)
- QNCX 352.5K
- RVPH 2.6M
- Earning Date
- QNCX 08-12-2025
- RVPH 08-13-2025
- Dividend Yield
- QNCX N/A
- RVPH N/A
- EPS Growth
- QNCX N/A
- RVPH N/A
- EPS
- QNCX N/A
- RVPH N/A
- Revenue
- QNCX N/A
- RVPH N/A
- Revenue This Year
- QNCX N/A
- RVPH N/A
- Revenue Next Year
- QNCX N/A
- RVPH N/A
- P/E Ratio
- QNCX N/A
- RVPH N/A
- Revenue Growth
- QNCX N/A
- RVPH N/A
- 52 Week Low
- QNCX $0.51
- RVPH $0.30
- 52 Week High
- QNCX $2.45
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- QNCX 64.95
- RVPH 31.07
- Support Level
- QNCX $1.48
- RVPH $0.35
- Resistance Level
- QNCX $1.68
- RVPH $0.40
- Average True Range (ATR)
- QNCX 0.14
- RVPH 0.07
- MACD
- QNCX 0.02
- RVPH -0.03
- Stochastic Oscillator
- QNCX 85.71
- RVPH 15.15
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.